Skip to main content
S&P 5007,683.11+1.51%DOW53,335.29+2.99%NASDAQ25,714.14+1.35%BTC$80,010.00+2.84%ETH$2,411.88+5.33%GOLD$4,071.00+3.31%OIL$88.69-7.70%
Smart Investors Daily
SID Premium
OB

NASDAQ · OBIO

Orchestra BioMed Holdings, Inc.

Healthcare · Biotechnology

$5.56

Up+$0.44 (+7.91%)

Updated Nov 4, 2026, 8:58 PM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
257.76M
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$3.46 – $6.50
Volume
273.79K
Avg. volume
309.78K

Price performance · OBIO

OBIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

OBIO closed at $5.56 after 21 trading sessions, down 4.79% for the selected period.

Last close
$5.56
Period change
-4.79%
Period low
$5.45
Period high
$6.09
Daily close
View OHLC price history
OBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$5.70$5.98$5.52$5.56273.79K
Nov 2, 2026$5.92$6.02$5.66$5.69317.5K
Oct 30, 2026$6.07$6.075$5.84$5.91232.43K
Oct 29, 2026$6.05$6.16$6.00$6.09274.57K
Oct 28, 2026$5.76$6.03$5.68$5.99428.4K
Oct 27, 2026$5.56$5.8418$5.52$5.78376.78K
Oct 26, 2026$5.58$5.655$5.52$5.55242.66K
Oct 23, 2026$5.46$5.66$5.39$5.59262.03K
Oct 22, 2026$5.72$5.7894$5.43$5.47390.88K
Oct 21, 2026$5.83$5.865$5.57$5.805485.98K
Oct 20, 2026$5.65$6.17$5.53$5.82992.78K
Oct 19, 2026$5.49$5.73$5.415$5.65226.59K
Oct 16, 2026$5.75$5.87$5.37$5.45473.66K
Oct 15, 2026$5.68$5.85$5.66$5.74253.38K
Oct 14, 2026$5.70$5.86$5.60$5.64222.88K
Oct 13, 2026$5.87$5.87$5.71$5.72204.82K
Oct 12, 2026$5.93$5.99$5.39$5.91237.99K
Oct 9, 2026$5.73$5.965$5.56$5.95229.32K
Oct 8, 2026$5.75$5.83$5.51$5.73241.88K
Oct 7, 2026$5.79$5.859$5.64$5.66241.25K
Oct 6, 2026$6.05$6.12$5.82$5.84213.12K

Latest OBIO news

The latest Smart Investors Daily articles mentioning OBIO.

Stock researchCompany · Overview

OBIO research

Overview

Company profile and research snapshot.

Company profile

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
13
OBIO recent ratings
DateFirmRatingTarget
Oct 23, 2026Chardan CapitalBuy—
Sep 15, 2026B. Riley SecuritiesBuy—
Sep 10, 2026BTIGBuy—
Aug 11, 2026Piper SandlerOverweight—
May 19, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB

Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on Nove

Yahoo · Oct 1, 2026

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By